Some breast cancer tumours resistant to chemotherapy

Some breast cancer tumours may be resistant to a common chemotherapy treatment, suggests recent medical research at the University of Alberta.

Principal investigator Ing Swie Goping and her team discovered some breast cancer tumours had low levels of certain genes, and that those tumours didn't respond well to taxane chemotherapy, a common treatment used in breast cancer.

"These tumours didn't shrink and were resistant to a common chemotherapy treatment. These results give us a strong incentive to continue our research," she said.

Goping and her team looked at tumour samples from 24 patients who had breast cancer. These patients were treated with chemotherapy before surgery. The team discovered four genes in the 'survival' system of tumour cells weren't functioning well in some of the samples. When parts of this system don't work the way they are supposed to, the tumour survival system gets weaker.

Researchers expected that because this survival system was weaker in some tumours, that chemotherapy treatment would be more effective at shrinking these tumours. But the opposite happened.

Is chemotherapy more effective?

Instead, they found that the stronger the tumours' survival system was, the better the chemotherapy worked.  "This discovery was a bit of a surprise," said Goping, a researcher in both the Department of Biochemistry and the Department of Oncology.

"One would expect that tumour cells with strong survival systems would be more chemotherapy-resistant, but that's not what we discovered." Goping noted this research was purely curiosity-driven, and the finding underscores the importance of basic research.

"It was a question we were asking at a very basic level and it turns out the discovery could be clinically relevant. At the moment there is no tool to determine which women would be good candidates for taxane chemotherapy. And chemotherapy resistance is a major clinical problem."

Goping hopes to continue this research by examining tumour samples from thousands of patients over a span of at least three years, in hopes of confirming what the team discovered is indeed a 'marker' that will predict which breast cancer patients will respond well to taxane chemotherapy.

She noted it would be years before doctors would be able to actually start testing breast cancer patients for this marker.

(EurekAlert, March 2012)

Read more:

Cancer

Cancer treatment

 

  

We live in a world where facts and fiction get blurred
In times of uncertainty you need journalism you can trust. For 14 free days, you can have access to a world of in-depth analyses, investigative journalism, top opinions and a range of features. Journalism strengthens democracy. Invest in the future today. Thereafter you will be billed R75 per month. You can cancel anytime and if you cancel within 14 days you won't be billed. 
Subscribe to News24
Voting Booth
The ANC's leadership race is heating up. Who do you think will be elected party president at Nasrec in December?
Please select an option Oops! Something went wrong, please try again later.
Results
Nkosazana Dlamini-Zuma has got it in the bag
7% - 719 votes
I foresee a second term for Cyril Ramaphosa
83% - 8473 votes
Don’t discount a Zweli Mkhize win
10% - 1012 votes
Vote
Rand - Dollar
17.77
-0.8%
Rand - Pound
20.13
+0.5%
Rand - Euro
17.57
+0.2%
Rand - Aus dollar
11.55
-0.7%
Rand - Yen
0.12
-0.4%
Gold
1,715.78
-0.6%
Silver
20.66
-1.9%
Palladium
2,260.50
-2.7%
Platinum
921.00
-1.3%
Brent Crude
91.80
+3.2%
Top 40
59,202
-1.1%
All Share
65,613
-1.1%
Resource 10
63,687
-1.4%
Industrial 25
79,239
-1.1%
Financial 15
13,961
-0.7%
All JSE data delayed by at least 15 minutes Iress logo
Editorial feedback and complaints

Contact the public editor with feedback for our journalists, complaints, queries or suggestions about articles on News24.

LEARN MORE